JP2018027920A - Pigment stem cell differentiation inhibitor, white hair preventing agent, and white hair evaluation method - Google Patents
Pigment stem cell differentiation inhibitor, white hair preventing agent, and white hair evaluation method Download PDFInfo
- Publication number
- JP2018027920A JP2018027920A JP2016161060A JP2016161060A JP2018027920A JP 2018027920 A JP2018027920 A JP 2018027920A JP 2016161060 A JP2016161060 A JP 2016161060A JP 2016161060 A JP2016161060 A JP 2016161060A JP 2018027920 A JP2018027920 A JP 2018027920A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- cxcl12
- expression level
- amino acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 161
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 54
- 239000000049 pigment Substances 0.000 title claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 30
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 230000024245 cell differentiation Effects 0.000 title description 15
- 238000011156 evaluation Methods 0.000 title description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims abstract description 106
- 230000014509 gene expression Effects 0.000 claims abstract description 100
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 69
- 239000000126 substance Substances 0.000 claims abstract description 28
- 230000004069 differentiation Effects 0.000 claims abstract description 26
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 26
- 230000002087 whitening effect Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000012216 screening Methods 0.000 claims abstract description 9
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000002752 melanocyte Anatomy 0.000 description 20
- 239000000203 mixture Substances 0.000 description 15
- 101150067717 CXCL12 gene Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 108010051081 dopachrome isomerase Proteins 0.000 description 7
- -1 jojoba oil Substances 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 5
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 108020004463 18S ribosomal RNA Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010807 real-time PCR kit Methods 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 210000000603 stem cell niche Anatomy 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000023895 stem cell maintenance Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013513 substance screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
本発明は、色素幹細胞の分化抑制剤、白髪の予防及び／又は改善剤、白髪化を評価する方法、ならびに白髪の予防及び／又は改善物質のスクリーニング方法等に関する。 The present invention relates to a pigment stem cell differentiation inhibitor, an agent for preventing and / or improving gray hair, a method for evaluating whitening, and a method for screening a substance for preventing and / or improving white hair.
ＣＸＣＬ１２（別名ｓｔｒｏｍａｌ ｃｅｌｌ−ｄｅｒｉｖｅｄ ｆａｃｔｏｒ−１：ＳＤＦ−１）は、細胞遊走活性を持ったサイトカインの一群であるケモカインの一種であり、特異的なＧタンパク質共役受容体ＣＸＣＲ４又はＣＸＣＲ７に結合する。ＣＸＣＬ１２は、リンパ球の遊走だけでなく、多岐にわたった活性を発揮し、心臓、神経及び血管の発生に必須であること、血管形成過程において内皮前駆細胞の動因に関与すること、骨髄における造血幹細胞の維持に関わることなどが知られている（非特許文献１）。一方、胚性幹細胞においては、ＣＸＣＬ１２がドーパミン作動性ニューロンへの分化を促進することが知られており（非特許文献２）、細胞種によってＣＸＣＬ１２の作用は異なる。 CXCL12 (also known as the cell-derived factor-1: SDF-1) is a kind of chemokine that is a group of cytokines having cell migration activity, and binds to a specific G protein-coupled receptor CXCR4 or CXCR7. CXCL12 exhibits not only lymphocyte migration but also a wide range of activities, is essential for the development of the heart, nerves and blood vessels, is involved in the pathogenesis of endothelial progenitor cells during angiogenesis, hematopoiesis in the bone marrow It is known to be involved in maintenance of stem cells (Non-patent Document 1). On the other hand, in embryonic stem cells, it is known that CXCL12 promotes differentiation into dopaminergic neurons (Non-patent Document 2), and the action of CXCL12 varies depending on the cell type.
皮膚や毛髪の色は、メラノサイトによって産生されるメラニンにより、大きく左右される。成体内のメラノサイトの起源は、毛包のバルジ領域に存在する色素幹細胞であることが知られている。色素幹細胞から分化したメラノブラストは、表皮や毛球へと移動し、Ｔｙｒｏｓｉｎａｓｅ（ＴＹＲ）、ＴＹＲ−ｒｅｌａｔｅｄ ｐｒｏｔｅｉｎ−１（ＴＹＲＰ１）及びＤｏｐａｃｈｒｏｍｅ ｔａｕｔｏｍｅｒａｓｅ（ＤＣＴ）などの一連のメラニン合成関連酵素の発現を獲得し、メラニン合成能を持った成熟したメラノサイトへ分化することで、それぞれ皮膚や毛髪の色素産生に関わる（非特許文献３）。したがって、色素幹細胞の維持や分化における異常は、白髪の原因となる。白髪化のメカニズムの一つとして、バルジ領域において色素幹細胞がメラノサイトへ異所性に分化してしまうことで、色素幹細胞が枯渇し、メラノサイトの供給源がなくなってしまうことが明らかになっている（非特許文献４）。一般的に、幹細胞は、ニッチと呼ばれる幹細胞の周囲を取り巻く微小環境によって制御されている（非特許文献５）。バルジ領域において、毛包幹細胞は色素幹細胞の周囲を取り囲むように存在し、色素幹細胞ニッチを形成している。したがって、毛包幹細胞の性質に着目し、色素幹細胞ニッチを適切に制御できれば、白髪化を予防又は改善する方法として、極めて有効である。また、バルジ領域に存在する毛包幹細胞は、頭部より抜去した毛髪に付着した毛根部に含まれており、酵素処理することによって得た細胞は、培養することができる（特許文献１）。 The color of skin and hair is greatly influenced by melanin produced by melanocytes. It is known that the origin of melanocytes in adults is pigment stem cells present in the bulge region of the hair follicle. Melanoblasts differentiated from pigment stem cells migrate to the epidermis and hair bulbs and acquire the expression of a series of melanin synthesis-related enzymes such as Tyrosinase (TYR), TYR-related protein-1 (TYRP1) and Dopachrome tautomerase (DCT) However, it differentiates into mature melanocytes having the ability to synthesize melanin, and is involved in pigment production of skin and hair, respectively (Non-patent Document 3). Therefore, abnormalities in the maintenance and differentiation of pigment stem cells cause gray hair. As one of the mechanisms of graying, it has been clarified that pigment stem cells are ectopically differentiated into melanocytes in the bulge region, leading to depletion of pigment stem cells and loss of the source of melanocytes ( Non-patent document 4). In general, stem cells are controlled by a microenvironment surrounding a stem cell called a niche (Non-patent Document 5). In the bulge region, hair follicle stem cells exist so as to surround the pigment stem cells and form a pigment stem cell niche. Therefore, paying attention to the properties of hair follicle stem cells and appropriately controlling the pigment stem cell niche is extremely effective as a method for preventing or improving gray hair. Moreover, the hair follicle stem cells present in the bulge region are contained in the hair root attached to the hair removed from the head, and the cells obtained by the enzyme treatment can be cultured (Patent Document 1).
従来の白髪の改善方法としては、毛包内に存在するメラノサイトを活性化し、メラニン生成やメラノサイトの増殖を促進する方法が主流であり、これらの方法には、毛髪のメラニン量を増加させる細胞増殖因子、植物抽出物、化合物などが適用されている（特許文献２−５）。しかしながら、これらの従来の方法による髪色の調節効果は、限定的又は対処療法的であり、より効果が高く根本的な白髪の改善方法の開発が望まれていた。 Conventional methods for improving gray hair include activating melanocytes in hair follicles and promoting melanogenesis and melanocyte growth. These methods include cell growth that increases the amount of melanin in the hair. Factors, plant extracts, compounds and the like are applied (Patent Documents 2-5). However, the effect of adjusting the hair color by these conventional methods is limited or coping therapy, and the development of a more effective and fundamental method for improving gray hair has been desired.
従って、本発明は、上述した実情に鑑み、白髪を根本的にかつ効率的に予防及び／又は改善する手段を提供することを課題とする。 Accordingly, an object of the present invention is to provide means for fundamentally and efficiently preventing and / or improving gray hair in view of the above-described circumstances.
本発明者らは上記課題を解決すべく鋭意研究を結果、毛包内バルジ領域においてＣＸＣＬ１２が特異的に発現していること、ＣＸＣＬ１２の発現量が黒髪の毛根部よりも白髪の毛根部で低いこと、毛包幹細胞により産生されたＣＸＣＬ１２が色素幹細胞の分化を抑制するとともに、メラノサイトの分化関連遺伝子の発現を抑制することを見出した。よって、ＣＸＣＬ１２は毛包内バルジ領域の色素幹細胞がメラノサイトへ異所性に分化することを抑制し、メラノサイトの供給源となる色素幹細胞の減少を阻止できるので、白髪の根本的な予防及び／又は改善に有効である。また、ＣＸＣＬ１２の発現を指標とすることにより、毛髪の白髪化の評価、白髪の予防及び／又は改善物質のスクリーニングや抗白髪剤の有効性の評価が可能である。本発明はかかる知見より完成されたものである。 As a result of intensive studies to solve the above problems, the present inventors have specifically expressed CXCL12 in the bulge region in the hair follicle, and the expression level of CXCL12 is lower in the hair root of white hair than in the hair root of black hair, It has been found that CXCL12 produced by hair follicle stem cells suppresses the differentiation of pigment stem cells and suppresses the expression of melanocyte differentiation-related genes. Therefore, since CXCL12 can suppress the ectopic differentiation of pigment stem cells in the bulge region in the hair follicle into melanocytes and prevent the decrease in pigment stem cells that are the source of melanocytes, It is effective for improvement. In addition, by using the expression of CXCL12 as an index, it is possible to evaluate whitening of hair, prevent white hair, and / or improve substance screening, and evaluate the effectiveness of anti-whitening agents. The present invention has been completed based on such findings.
すなわち、本発明は、以下の発明を包含する。
［１］ＣＸＣＬ１２（ｓｔｒｏｍａｌ ｃｅｌｌ-ｄｅｒｉｖｅｄ ｆａｃｔｏｒ−１）を有効成分として含有することを特徴とする、毛包内バルジ領域の色素幹細胞の分化抑制剤。
［２］ＣＸＣＬ１２（ｓｔｒｏｍａｌ ｃｅｌｌ-ｄｅｒｉｖｅｄ ｆａｃｔｏｒ−１）を有効成分として含有することを特徴とする、白髪の予防及び／又は改善剤。
［３］前記ＣＸＣＬ１２が、以下の(ａ)〜(ｃ)のいずれかのタンパク質又はその部分ペプチドである、［１］又は［２］に記載の剤。
(ａ) 配列番号２に示すアミノ酸配列からなるタンパク質
(ｂ) 配列番号２に示すアミノ酸配列において、１若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質
(ｃ) 配列番号２に示すアミノ酸配列と８０％以上の配列同一性を有するアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質
［４］被験対象より採取した毛髪の毛根部におけるＣＸＣＬ１２の発現量を指標として、毛髪の白髪化を評価する方法。
［５］被験対象に抗白髪剤を使用し、使用する前と後の該被験対象より採取した毛髪の毛根部におけるＣＸＣＬ１２の発現量を指標として、毛髪に対する抗白髪剤の有効性を評価する方法。
［６］以下の工程を含む、白髪の予防及び／又は改善物質のスクリーニング方法。
（１）被験物質を毛髪の毛根部と接触させて培養する工程
（２）上記毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（３）被験物質を接触させない毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（４）上記工程（２）で測定した発現量が、上記工程（３）で測定した発現量より増加した被験物質を白髪の予防及び／又は改善物質として選択する工程
［７］前記ＣＸＣＬ１２の発現量が、前記毛根部から抽出したｍＲＮＡを試料とし、ＰＣＲ法によって測定される、［４］〜［６］のいずれかに記載の方法。
［８］前記ＣＸＣＬ１２の発現量が、前記毛根部から抽出したタンパク質を試料とし、免疫学的方法によって測定される、［４］〜［６］のいずれかに記載の方法。
That is, the present invention includes the following inventions.
[1] An agent for suppressing the differentiation of pigment stem cells in the hair follicle bulge region, comprising CXCL12 (stromal cell-derived factor-1) as an active ingredient.
[2] A preventive and / or ameliorating agent for gray hair, comprising CXCL12 (stromal cell-derived factor-1) as an active ingredient.
[3] The agent according to [1] or [2], wherein the CXCL12 is any one of the following proteins (a) to (c) or a partial peptide thereof.
(a) a protein comprising the amino acid sequence shown in SEQ ID NO: 2
(b) a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence shown in SEQ ID NO: 2 and having differentiation-inhibiting activity of pigment stem cells in the bulge region in the hair follicle
(c) a protein comprising an amino acid sequence having 80% or more of sequence identity with the amino acid sequence shown in SEQ ID NO: 2 and having a pigment stem cell differentiation inhibitory activity in the hair follicle bulge region [4] Hair collected from a test subject A method for evaluating whitening of hair using the expression level of CXCL12 in the hair root as an index.
[5] A method for evaluating the effectiveness of an anti-whitening agent on hair using an anti-whitening agent as a test subject, and using the expression level of CXCL12 in the hair root of the hair collected from the test subject before and after use as an index.
[6] A screening method for a substance for preventing and / or improving gray hair, comprising the following steps.
(1) The step of culturing the test substance in contact with the hair root part (2) The step of measuring the expression level of CXCL12 in the hair root part (3) The step of measuring the expression level of CXCL12 in the hair root part not contacting the test substance (4) A step of selecting a test substance whose expression level measured in the step (2) is higher than the expression level measured in the step (3) as a white hair prevention and / or improvement substance [7] Expression of the CXCL12 The method according to any one of [4] to [6], wherein the amount is measured by a PCR method using mRNA extracted from the hair root as a sample.
[8] The method according to any one of [4] to [6], wherein the expression level of the CXCL12 is measured by an immunological method using the protein extracted from the hair root as a sample.
ＣＸＣＬ１２は、色素幹細胞のニッチ（幹細胞の生態的適所）である毛包内バルジ領域に存在し、本来は未分化な状態が維持される色素幹細胞の分化を顕著に抑制することができる。よって、本発明によれば、ＣＸＣＬ１２を有効成分とする毛包内バルジ領域の色素幹細胞の分化抑制剤、白髪の予防及び／又は改善剤が提供される。また、ＣＸＣＬ１２の発現を指標とすることにより、毛髪の白髪化の評価、白髪の予防及び／又は改善物質のスクリーニングや抗白髪剤の有効性の評価が可能となる。 CXCL12 exists in the bulge region in the hair follicle, which is a pigment stem cell niche (stem cell ecological position), and can significantly suppress the differentiation of pigment stem cells that are originally maintained in an undifferentiated state. Therefore, according to the present invention, there are provided a pigment stem cell differentiation inhibitor and a gray hair prevention and / or amelioration agent in the hair follicle bulge region containing CXCL12 as an active ingredient. In addition, by using the expression of CXCL12 as an index, it is possible to evaluate whitening of hair, prevent white hair, and / or screen for improving substances and evaluate the effectiveness of anti-whitening agents.
１．色素幹細胞の分化抑制剤、白髪の予防及び／又は改善剤
本発明の色素幹細胞の分化抑制剤は、ＣＸＣＬ１２を有効成分として含有し、色素幹細胞のニッチ（幹細胞の生態的適所）である毛包内バルジ領域の色素幹細胞の分化を抑制できる。
1. Pigment stem cell differentiation inhibitor, agent for preventing and / or improving gray hair The pigment stem cell differentiation inhibitor of the present invention contains CXCL12 as an active ingredient, and is contained in a hair follicle that is a pigment stem cell niche (stem cell ecological position). Differentiation of pigment stem cells in the bulge region can be suppressed.
本発明において「色素幹細胞の分化抑制」とは、本来未分化な状態で維持される毛包内バルジ領域（ニッチ）における色素幹細胞の異所性分化の抑制、及び未分化性の維持を意味する。 In the present invention, “inhibition of differentiation of pigment stem cells” means suppression of ectopic differentiation of pigment stem cells in the bulge region (niche) in the hair follicle that is originally maintained in an undifferentiated state, and maintenance of undifferentiation. .
本発明の色素幹細胞の分化抑制剤の有効成分であるＣＸＣＬ１２（別名stromal-derived factor-1：ＳＤＦ−１）は、細胞遊走活性を持ったサイトカインの一群であるケモカインの一種である。ＣＸＣＬ１２タンパク質のアミノ酸配列、及びＣＸＣＬ１２をコードする遺伝子（ＣＸＣＬ１２遺伝子）の塩基配列は既に知られており、データベースに登録されている（Homo sapiens C-X-C motif chemokine ligand 12：Genbank number: Nucleotide NM_199168; Protein NP_954637.1）。ＣＸＣＬ１２遺伝子の塩基配列は配列番号１に示される通りであり、ＣＸＣＬ１２タンパク質は配列番号１の塩基配列の９３番目から３６２番目までの領域によってコードされ、そのアミノ酸配列は配列番号２に示される通りである。本明細書において「ＣＸＣＬ１２遺伝子」とは、上記塩基配列で特定されるヒト由来の遺伝子をいい、「ＣＸＣＬ１２」又は「ＣＸＣＬ１２タンパク質」とは、該ＣＸＣＬ１２遺伝子がコードし、上記アミノ酸配列で特定されるタンパク質をいう。 CXCL12 (also known as stroma-derived factor-1: SDF-1), which is an active ingredient of the pigment stem cell differentiation inhibitor of the present invention, is a type of chemokine that is a group of cytokines having cell migration activity. The amino acid sequence of the CXCL12 protein and the base sequence of the gene encoding CXCL12 (CXCL12 gene) are already known and registered in the database (Homo sapiens CXC motif chemokine ligand 12: Genbank number: Nucleotide NM_199168; Protein NP_954637. 1). The base sequence of the CXCL12 gene is as shown in SEQ ID NO: 1, the CXCL12 protein is encoded by the region from the 93rd to the 362rd base sequence of SEQ ID NO: 1, and the amino acid sequence is as shown in SEQ ID NO: 2. is there. In the present specification, “CXCL12 gene” refers to a human-derived gene specified by the above nucleotide sequence, and “CXCL12” or “CXCL12 protein” is encoded by the CXCL12 gene and specified by the above amino acid sequence. It refers to protein.
本発明において用いるＣＸＣＬ１２タンパク質は、毛包内バルジ領域の色素幹細胞の分化抑制作用を有する限り、その相同タンパク質であってもよく、相同タンパク質もまた、本発明にいうＣＸＣＬ１２タンパク質に包含されるものとする。相同タンパク質としては、例えば、配列番号２に示すアミノ酸配列において、１若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質、配列番号２に示すアミノ酸配列と８０％以上の配列同一性を有するアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質が挙げられる。 The CXCL12 protein used in the present invention may be a homologous protein as long as it has a pigment stem cell differentiation inhibitory action in the bulge region in the hair follicle, and the homologous protein is also included in the CXCL12 protein referred to in the present invention. To do. Examples of the homologous protein include an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence shown in SEQ ID NO: 2, and have an activity of inhibiting the differentiation of pigment stem cells in the hair follicle bulge region. And a protein having an amino acid sequence having 80% or more of sequence identity with the amino acid sequence shown in SEQ ID NO: 2 and having an activity of inhibiting differentiation of pigment stem cells in the bulge region in the hair follicle.
ＣＸＣＬ１２タンパク質の相同タンパク質は、上記に定義される構造と機能を有する限り、由来は問わず、ヒト以外の哺乳動物由来であってもよく、ヒトなどの哺乳動物由来の遺伝子に対して人工的に変異を導入したものであってもよい。 As long as the homologous protein of CXCL12 protein has the structure and function defined above, it may be derived from mammals other than humans, and may be artificially derived from genes derived from mammals such as humans. A mutation may be introduced.
上記の「１若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列」における「１若しくは数個」の範囲は特には限定されないが、部位特異的突然変異誘発法等の公知の変異導入法により欠失、置換、若しくは付加できる程度の数のアミノ酸をいい、例えば、１から２０個、好ましくは１から１０個、より好ましくは１から７個、さらに好ましくは１から５個、特に好ましくは１から３個程度を意味する。また、上記の「８０％以上の配列同一性」とは、好ましくは８５％以上、より好ましくは９０％以上、さらに好ましくは９５％以上、最も好ましくは９８％以上の配列同一性をいう。配列同一性の値は、複数のアミノ酸配列間の同一性を演算するソフトウェア（例えば、ＦＡＳＴＡ、ＢＬＡＳＴ、ＤＡＮＡＳＹＳ）を用いてデフォルトの設定で算出した値を示す。 The range of “one or several” in the above “amino acid sequence in which one or several amino acids are deleted, substituted or added” is not particularly limited, but known mutation introduction such as site-directed mutagenesis The number of amino acids that can be deleted, substituted, or added by the method. For example, 1 to 20, preferably 1 to 10, more preferably 1 to 7, more preferably 1 to 5, particularly preferably Means about 1 to 3 pieces. The “80% or more sequence identity” is preferably 85% or more, more preferably 90% or more, still more preferably 95% or more, and most preferably 98% or more. The value of sequence identity indicates a value calculated with default settings using software (for example, FASTA, BLAST, DANASYS) that calculates identity between a plurality of amino acid sequences.
ＣＸＣＬ１２タンパク質は、配列番号２に示すアミノ酸配列の一部の配列からなる部分ペプチドであってもよい。そのような部分ペプチドの長さは、上記の色素幹細胞の分化抑制活性を有する限り特に限定されないが、例えば、配列番号２に示すアミノ酸配列の少なくとも１０個、好ましくは少なくとも１５個、より好ましくは少なくとも２０個以上の連続したアミノ酸からなるペプチドが挙げられる。これらの部分ペプチドは、公知のペプチド合成法又は適当なペプチダーゼ（例えば、トリプシン、キモトリプシン等）で全長のアミノ酸配列を切断することによって製造することができる。ペプチド合成法としては、例えば、固相合成法、液相合成法のいずれであってもよい。 The CXCL12 protein may be a partial peptide consisting of a partial sequence of the amino acid sequence shown in SEQ ID NO: 2. The length of such a partial peptide is not particularly limited as long as it has the above-described pigment stem cell differentiation-inhibiting activity. For example, at least 10, preferably at least 15, and more preferably at least 15 of the amino acid sequence shown in SEQ ID NO: 2. Peptides consisting of 20 or more consecutive amino acids can be mentioned. These partial peptides can be produced by cleaving the full-length amino acid sequence by a known peptide synthesis method or an appropriate peptidase (for example, trypsin, chymotrypsin, etc.). The peptide synthesis method may be, for example, either a solid phase synthesis method or a liquid phase synthesis method.
ＣＸＣＬ１２は、毛包内バルジ領域の色素幹細胞の分化抑制により、メラノサイトの供給源となる色素幹細胞の減少又は枯渇を阻止できるので、白髪の予防及び／又は改善剤の有効成分とすることができる。本発明の白髪の予防及び／又は改善剤の有効成分となるＣＸＣＬ１２タンパク質及びその相同タンパク質は、前述のとおりである。 CXCL12 can be used as an active ingredient for the prevention and / or improvement of gray hair because inhibition of differentiation of pigment stem cells in the bulge region in the hair follicle can prevent decrease or depletion of pigment stem cells serving as a melanocyte supply source. The CXCL12 protein and its homologous protein that are active ingredients of the agent for preventing and / or improving gray hair of the present invention are as described above.
本発明において、「白髪の予防及び／又は改善」には、白髪発生の阻止、白髪の程度（本数や範囲）の改善、白髪化の進行速度の低下、白髪から黒髪への変化、白髪に伴う脱毛の抑制、白髪に伴う毛髪の光沢や弾性の減少の抑制などが含まれる。また、白髪の予防及び／又は改善効果は、頭髪に直接な作用機序を示す場合と頭部における経皮的な作用機序を示す場合の両方を含む。 In the present invention, “prevention and / or improvement of white hair” includes prevention of white hair generation, improvement of the degree (number and range) of white hair, reduction in the progress of whitening, change from white hair to black hair, accompanied by white hair. Examples include suppression of hair loss, suppression of decrease in gloss and elasticity of hair associated with white hair. Moreover, the prevention and / or improvement effect of gray hair includes both the case of showing a direct action mechanism on the hair and the case of showing a percutaneous action mechanism on the head.
本発明の色素幹細胞の分化抑制剤は、例えば、色素幹細胞の維持及び分化のメカニズム、白髪発生のメカニズム、抗白髪剤の作用機序の解明を目的として色素幹細胞を培養する際の培地添加剤として使用することができる。また、本発明の白髪の予防及び／又は改善剤は、そのまま使用することも可能であるが、本発明の効果を損なわない範囲で適当な添加物等と混合し、化粧品、医薬部外品、医薬品などの組成物の形態とすることができる。なかでも、頭皮や毛髪に使用するのに適した製剤形態に製剤化した毛髪用組成物が好ましい。 The pigment stem cell differentiation inhibitor of the present invention is, for example, as a medium additive for culturing pigment stem cells for the purpose of elucidating the mechanism of pigment stem cell maintenance and differentiation, the mechanism of gray hair generation, and the mechanism of action of anti-white hair agents. Can be used. Further, the agent for preventing and / or improving gray hair of the present invention can be used as it is, but is mixed with an appropriate additive or the like within a range not impairing the effects of the present invention, and is used in cosmetics, quasi drugs, It can be in the form of a composition such as a pharmaceutical product. Especially, the composition for hair formulated into the formulation form suitable for using for a scalp and hair is preferable.
毛髪用組成物は、皮膚外用組成物において通常使用されている各種の成分、添加剤、基剤等をその種類に応じて選択し、適宜配合し、当分野で公知の手法に従って製造することができる。配合する成分、添加剤、基材としては、例えば、希釈剤（精製水、エタノール等）、油脂類（オリーブ油、ヤシ油、月見草油、ホホバ油、ヒマシ油、硬化ヒマシ油等）、ロウ類（ラノリン、ミツロウ、カルナウバロウ等）、炭化水素類（流動パラフィン、スクワレン、スクワラン、ワセリン等）、脂肪酸類（ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸等）、高級アルコール類（ミリスチルアルコール、セタノール、セトステアリルアルコール、ステアリルアルコール、ベヘニルアルコール等）、エステル類（ミリスチン酸イソプロピル、パルミチン酸イソプロピル、オクタン酸セチル、トリオクタン酸グリセリン、ミリスチン酸オクチルドデシル、ステアリン酸オクチル、ステアリン酸ステアリル等）、有機酸類（クエン酸、乳酸、α-ヒドロキシ酢酸、ピロリドンカルボン酸等）、糖類（マルチトール、ソルビトール、キシロビオース、N-アセチル-D-グルコサミン等）、界面活性剤、シリコーン油、保湿剤、増粘剤、紫外線吸収剤、金属イオン封鎖剤、清涼化剤、抗酸化剤、安定化剤、防腐剤、消炎剤、殺菌剤、香料、着色料等が挙げられる。 The composition for hair can be produced according to a method known in the art by selecting various ingredients, additives, bases, and the like that are usually used in an external composition for skin according to the type and mixing them appropriately. it can. Components, additives, and base materials to be blended include, for example, diluents (purified water, ethanol, etc.), fats and oils (olive oil, palm oil, evening primrose oil, jojoba oil, castor oil, hardened castor oil, etc.), waxes ( Lanolin, beeswax, carnauba wax, etc.), hydrocarbons (liquid paraffin, squalene, squalane, petrolatum, etc.), fatty acids (lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, etc.), higher alcohols (myristyl alcohol, Cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, etc.), esters (isopropyl myristate, isopropyl palmitate, cetyl octoate, glyceryl trioctanoate, octyldodecyl myristate, octyl stearate, stearyl stearate, etc.), organic acids Citric acid, lactic acid, α-hydroxyacetic acid, pyrrolidone carboxylic acid, etc.), saccharides (maltitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, etc.), surfactant, silicone oil, humectant, thickener, UV Examples include absorbents, sequestering agents, cooling agents, antioxidants, stabilizers, preservatives, flame retardants, bactericides, fragrances, and coloring agents.
また、上記毛髪用組成物には、本発明の効果に悪影響を及ぼさない限り、育毛料・養毛料の成分として従来より知られている成分を含めてもよい。例えば、センブリエキス、ニンジン抽出液等の植物抽出エキス、ビタミンＢ６、ビタミンＥ及びその誘導体、ビオチン等のビタミン類、パントテン酸及びその誘導体、グリチルリチン酸及びその誘導体、ニコチン酸エステル、セリン、メチオニン等のアミノ酸類、セフォランチン、塩化カプロニウム、ミノキシジル、ニコランジル、アセチルコリン誘導体、サイクロスポリン類、及びエストラジオール等の女性ホルモン剤等、ならびにこれらの混合物が挙げられる。 Moreover, as long as the said composition for hair does not have a bad influence on the effect of this invention, you may include the component conventionally known as a component of hair restorer and a hair nourishing agent. For example, plant extract such as assembly extract, carrot extract, vitamin B 6 , vitamin E and its derivatives, vitamins such as biotin, pantothenic acid and its derivatives, glycyrrhizic acid and its derivatives, nicotinic acid ester, serine, methionine, etc. Amino acid, ceforanthin, capronium chloride, minoxidil, nicorandil, acetylcholine derivatives, cyclosporine, and female hormone agents such as estradiol, and mixtures thereof.
本発明において、毛髪用組成物は、頭皮や毛髪に使用するものを広く指し、頭皮や毛髪に適用可能なものであればいずれでもよく、剤型は特に問わない。例えば、液状、乳液状、クリーム状、ゲル状、ペースト状、スプレー状等のいずれであってもよい。具体的な製品形態としては、クリーム、ローション、乳剤、軟膏、ゲル、ヘアシャンプー、ヘアリンス、ヘアトリートメント、ヘアコンディショナー、スカルプトリートメント、ヘアスプレー、ヘアパック、ヘアエッセンス、ヘアトニック、ヘアリキッド、ヘアムースなどが挙げられる。 In the present invention, the hair composition widely refers to those used for the scalp and hair, and any composition can be used as long as it is applicable to the scalp and hair, and the dosage form is not particularly limited. For example, any of liquid, emulsion, cream, gel, paste, spray and the like may be used. Specific product forms include cream, lotion, emulsion, ointment, gel, hair shampoo, hair rinse, hair treatment, hair conditioner, scalp treatment, hair spray, hair pack, hair essence, hair tonic, hair liquid, hair mousse, etc. Can be mentioned.
これらの製品形態をとる組成物中のＣＸＣＬ１２の含有量は、形態に応じて異なるので特定することはできないが、一般に、組成物の総重量に対し、０．０００１〜２０重量％、好ましくは０．００１〜１０重量％である。ＣＸＣＬ１２の添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。 The content of CXCL12 in compositions in these product forms cannot be specified because it varies depending on the form, but is generally 0.0001 to 20% by weight, preferably 0, based on the total weight of the composition 0.001 to 10% by weight. The method for adding CXCL12 may be added in advance or during the production, and may be appropriately selected in consideration of workability.
２．毛髪の白髪化を評価する方法、毛髪に対する抗白髪剤の有効性を評価する方法
本発明の毛髪の白髪化を評価する方法は、被験対象より採取した毛髪の毛根部における
ＣＸＣＬ１２の発現量を指標として用いる。具体的には、被験対象の特定部位の毛髪より採取した毛根部を用意し、該毛根部におけるＣＸＣＬ１２の発現量を測定し、該発現量に基づいて毛髪の白髪化を評価する。本発明において「白髪化の評価」とは、白髪の発生の予測、白髪になる素因の有無の判定、白髪の程度（本数や範囲）の判定、白髪化の進行度の判定などをいう。
2. Method for evaluating whitening of hair, method for evaluating effectiveness of anti-whitening agent for hair The method for evaluating whitening of hair of the present invention is based on the expression level of CXCL12 in the hair root of the hair sampled from the test subject. Use. Specifically, a hair root part collected from the hair of a specific part to be tested is prepared, the expression level of CXCL12 in the hair root part is measured, and whitening of the hair is evaluated based on the expression level. In the present invention, “evaluation of whitening” refers to prediction of the occurrence of white hair, determination of the presence or absence of a predisposition to whitening, determination of the degree (number or range) of white hair, determination of the degree of progress of whitening.
評価は、被験対象の毛髪の毛根部（被験対象試料）におけるＣＸＣＬ１２の発現量を対照試料におけるＣＸＣＬ１２量と比較することにより行う。対照試料とは、比較の基準となる試料をいい、例えば、黒髪の毛根部、白髪の毛根部のいずれであってもよく、それらの対照試料のＣＸＣＬ１２の発現量を基準発現量として定めておく。例えば被験対象試料のＣＸＣＬ１２の発現量が、予め基準発現量として定めた黒髪の毛根部におけるＣＸＣＬ１２の発現量よりも有意に低い場合、又は、白髪の毛根部におけるＣＸＣＬ１２の発現量と同等である場合、当該被験対象は、近い将来白髪が発生する、又は白髪になりやすい素因を有すると評価できる。また、被験対象のＣＸＣＬ１２の発現量が、予め基準発現量として定めた黒髪の毛根部におけるＣＸＣＬ１２の発現量と同等である場合、又は、白髪の毛根部におけるＣＸＣＬ１２の発現量よりも有意に高い場合、当該被験対象は、近い将来白髪が発生しない、白髪になりにくい素因を有すると評価できる。 The evaluation is performed by comparing the expression level of CXCL12 in the hair root of the test subject hair (test target sample) with the CXCL12 amount in the control sample. The control sample refers to a sample serving as a reference for comparison, and may be, for example, the root of black hair or the root of white hair, and the expression level of CXCL12 in these control samples is determined as the reference expression level. For example, when the expression level of CXCL12 in the test target sample is significantly lower than the expression level of CXCL12 in the hair root of black hair, which is determined in advance as the reference expression level, or when the expression level of CXCL12 in the hair root of white hair is equivalent to The test subject can be evaluated as having a predisposition to developing gray hair or becoming gray hair in the near future. In addition, when the expression level of CXCL12 of the test subject is equivalent to the expression level of CXCL12 in the hair root of black hair, which is determined in advance as the reference expression level, or when significantly higher than the expression level of CXCL12 in the hair root of gray hair, It can be evaluated that the test subject has a predisposition to not become gray hair in the near future, and difficult to become gray hair.
被験対象試料のＣＸＣＬ１２の発現量は、絶対値又は相対値（比較対照又は基準発現量との比率や差など）として算出され、必ずしもＣＸＣＬ１２の絶対的な発現量を測定する必要はなく、対照試料のＣＸＣＬ１２の発現量との相対的な関係が明らかになれば十分である。 The expression level of CXCL12 in the test sample is calculated as an absolute value or a relative value (such as a ratio or difference from a comparison control or reference expression level), and it is not always necessary to measure the absolute expression level of CXCL12. It is sufficient if the relative relationship with the expression level of CXCL12 is clarified.
上記の評価において、被験対象試料のＣＸＣＬ１２の発現量が、基準発現量と比べて、例えば、１０％、又は２０％、又は３０％、又は５０％、又は７０％、又は１００％高い又は低い場合、有意に高い、又は、有意に低いとすることができる。また、ここでいう「評価」は、医師による診断を包含せず、年齢等とは関係なく甲状腺機能低下症などの特定の疾患によって発症する白髪に対して医師による診断が介入する場合であっても、診断の補助を意味し、具体的には、診断のためのデータを取得することをいう。 In the above evaluation, when the expression level of CXCL12 in the test sample is 10%, or 20%, or 30%, or 50%, or 70%, or 100% higher or lower than the reference expression level, for example , Significantly higher or significantly lower. In addition, “evaluation” here does not include diagnosis by a doctor, and the diagnosis by a doctor intervenes for gray hair caused by a specific disease such as hypothyroidism regardless of age or the like. Also means diagnosis assistance, specifically, obtaining data for diagnosis.
また、本発明の毛髪に対する抗白髪剤の有効性を評価する方法は、被験対象に抗白髪剤を使用し、使用する前と後の該被験対象より採取した毛髪の毛根部におけるＣＸＣＬ１２の発現量の変化を指標とする。具体的には、抗白髪剤を使用する前の被験対象の特定部位の毛髪より採取した毛根部、抗白髪剤を一定期間使用した後の同被験対象の特定部位の毛髪より採取した毛根部を用意し、２つの毛根部におけるＣＸＣＬ１２の発現量をそれぞれ測定し、該発現量の差に基づいて毛髪に対する抗白髪剤の有効性を評価する。例えば、抗白髪剤を使用した後の被験対象のＣＸＣＬ１２の発現量が、抗白髪剤を使用する前の被験対象のＣＸＣＬ１２の発現量よりも有意に増加した場合は、該抗白髪剤は、白髪の予防及び／又は改善に有効であると評価できる。 In addition, the method for evaluating the effectiveness of the anti-whitening agent on the hair of the present invention uses an anti-whitening agent for the test subject, and the expression level of CXCL12 in the hair root of the hair sampled from the test subject before and after use. Change is used as an index. Specifically, the hair root part collected from the hair of the specific part of the test subject before using the anti-whitening agent, the hair root part collected from the hair of the specific part of the test subject after using the anti-white hair agent for a certain period of time Prepare and measure the expression level of CXCL12 in the two hair roots, respectively, and evaluate the effectiveness of the anti-whitening agent on the hair based on the difference in the expression level. For example, if the expression level of CXCL12 in the test subject after using the anti-white hair agent is significantly higher than the expression level of CXCL12 in the test subject before using the anti-white hair agent, the anti-white hair agent It can be evaluated that it is effective for prevention and / or improvement.
上記の毛髪の白髪化を評価する方法、毛髪に対する抗白髪剤の有効性を評価する方法において、被験対象は典型的にはヒトであるが、ヒト以外の動物であってもよい。ヒト以外の動物の具体例として、サル、イヌ、ネコ、マウス、ラット、モルモット、ウサギ等を挙げることができる。 In the method for evaluating whitening of the hair and the method for evaluating the effectiveness of the anti-whitening agent on the hair, the test subject is typically a human, but may be an animal other than a human. Specific examples of animals other than humans include monkeys, dogs, cats, mice, rats, guinea pigs, rabbits and the like.
また、毛髪からの毛根部の採取方法は特に限定されないが、例えば、引き抜いた毛髪や自然脱落した毛髪から毛根部を採取することができる。 Further, the method for collecting the hair root portion from the hair is not particularly limited. For example, the hair root portion can be collected from the extracted hair or the hair that is naturally removed.
毛髪の毛根部におけるＣＸＣＬ１２の発現量の測定方法は特に限定されない。例えば、ＣＸＣＬ１２遺伝子の発現量やＣＸＣＬ１２タンパク質の発現量を測定する方法が挙げられる。 The measuring method of the expression level of CXCL12 in the hair root part is not particularly limited. For example, the method of measuring the expression level of CXCL12 gene and the expression level of CXCL12 protein is mentioned.
本発明において、被験対象試料及び対照試料における遺伝子の発現量は、当業者に公知の任意の方法により測定することができ、また、測定は、各方法の常法に従って実施すればよい。遺伝子の発現量とは、遺伝子の転写産物であるｍＲＮＡ量をいう。ｍＲＮＡ量の測定は、所望のｍＲＮＡ量を測定できる方法であれば特に限定されず、公知の方法から適宜選択して用いることができる。例えば、ＣＸＣＬ１２遺伝子にハイブリダイズするオリゴヌクレオチドをプライマーとした遺伝子増幅法、又は、ＣＸＣＬ１２遺伝子にハイブリダイズするオリゴ（ポリ）ヌクレオチドをプローブとしたハイブリダイゼーション法を利用することができる。具体的には、ＲＴ−ＰＣＲ法、リアルタイムＲＴ−ＰＣＲ法、マイクロアレイ法、ノーザンブロット法、ドットブロット法、ＲＮアーゼプロテクションアッセイ法などが挙げられる。上記の方法に用いるプライマーやプローブは、標識し、当該標識のシグナル強度を調べることによりｍＲＮＡ量を測定することができる。なかでも、リアルタイムＲＴ−ＰＣＲ法はＲＮＡを直接サンプルに使用でき、遺伝子増幅過程を光学的に測定することで増幅に必要な温度サイクルの回数から遺伝子定量が可能である上で好ましい。なお、上記の方法に用いるプライマーおよびプローブは前記のＣＸＣＬ１２遺伝子の塩基配列（配列番号１）に基づいて当業者であれば適宜設計し、調製することができる。各方法について様々なプロトコルが報告されており、当業者であれば公知のプロトコルに従い、又は公知のプロトコルを適宜修正や変更を行い実施することができる。 In the present invention, the gene expression level in the test sample and the control sample can be measured by any method known to those skilled in the art, and the measurement may be carried out according to a conventional method of each method. The expression level of a gene refers to the amount of mRNA that is a transcription product of the gene. The measurement of the amount of mRNA is not particularly limited as long as it can measure the desired amount of mRNA, and can be appropriately selected from known methods. For example, a gene amplification method using an oligonucleotide hybridizing to the CXCL12 gene as a primer or a hybridization method using an oligo (poly) nucleotide hybridizing to the CXCL12 gene as a probe can be used. Specifically, RT-PCR method, real-time RT-PCR method, microarray method, Northern blot method, dot blot method, RNase protection assay method and the like can be mentioned. Primers and probes used in the above method can be labeled, and the amount of mRNA can be measured by examining the signal intensity of the label. Among these, the real-time RT-PCR method is preferable because RNA can be directly used for a sample, and gene quantification can be performed from the number of temperature cycles required for amplification by optically measuring the gene amplification process. The primer and probe used in the above method can be appropriately designed and prepared by those skilled in the art based on the base sequence (SEQ ID NO: 1) of the CXCL12 gene. Various protocols have been reported for each method, and those skilled in the art can implement according to a known protocol or by appropriately modifying or changing the known protocol.
タンパク質の発現量の測定は、例えば、ＣＸＣＬ１２タンパク質に対する抗体又は抗体断片を用いて免疫学的に測定する方法を用いることができる。具体的には、ブロッティング法、ドットブロット法、プロテインアレイ、免疫沈降法、酵素免疫測定法（ＥＬＩＳＡ）、放射線免疫測定法（ＲＩＡ）、蛍光抗体法、免疫細胞染色等を挙げることができる。これらの方法についても、常法のプロトコール、又は常法のプロトコールを適宜修正・変更したプロトコールによって実施することができる。 The protein expression level can be measured by, for example, an immunological method using an antibody or antibody fragment against CXCL12 protein. Specific examples include a blotting method, a dot blot method, a protein array, an immunoprecipitation method, an enzyme immunoassay method (ELISA), a radioimmunoassay method (RIA), a fluorescent antibody method, and immune cell staining. These methods can also be carried out by a conventional protocol or a protocol obtained by appropriately modifying or changing a conventional protocol.
本発明の方法に用いる上記ＣＸＣＬ１２の発現量を測定するための試薬を予め組み合わせてキット化することもできる。例えば、キットには、ＰＣＲに用いるプライマーセット、プローブとして用いるポリ（オリゴ）ヌクレオチド、又は抗体のいずれかを少なくとも含んでいればよい。また、該キットには、必要に応じて、ＲＮＡ抽出用試薬、ＰＣＲ用緩衝液やＤＮＡポリメラーゼ等のＰＣＲ用試薬、染色剤や電気泳動用ゲル等の検出用試薬、固定化担体、標識物質、標識の検出に用いられる基質化合物、陽性や陰性の標準試料、キットの使用方法を記載した指示書等を含めることもできる。なお、キット中の試薬は溶液でも凍結乾燥物でもよい。 Reagents for measuring the expression level of CXCL12 used in the method of the present invention can be combined in advance to form a kit. For example, the kit may contain at least one of a primer set used for PCR, a poly (oligo) nucleotide used as a probe, or an antibody. In addition, the kit contains RNA extraction reagents, PCR reagents such as PCR buffers and DNA polymerase, detection reagents such as stains and electrophoresis gels, immobilization carriers, labeling substances, Substrate compounds used for detection of the label, positive and negative standard samples, instructions describing how to use the kit, and the like can also be included. The reagent in the kit may be a solution or a lyophilized product.
３．白髪の予防及び／又は改善物質のスクリーニング方法
ＣＸＣＬ１２は、白髪の予防及び／又は改善物質のスクリーニング方法にも使用できる。本発明のスクリーニング方法によれば、ＣＸＣＬ１２の発現の亢進を指標として、白髪の予防及び／又は改善物質を精度よく、かつ迅速、正確にスクーニングできる。本発明のスクリーニング方法は、具体的には以下の工程を含む。
（１）被験物質を毛髪の毛根部と接触させて培養する工程
（２）上記毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（３）被験物質を接触させない毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（４）上記工程（２）で測定した発現量が、上記工程（３）で測定した発現量より増加した被験物質を白髪の予防及び／又は改善物質として選択する工程
3. Method for Screening Substances for Preventing and / or Improving White Hair CXCL12 can also be used as a method for screening substances for preventing and / or improving white hair. According to the screening method of the present invention, a white hair prevention and / or ameliorating substance can be accurately, rapidly and accurately screened using the increased expression of CXCL12 as an index. Specifically, the screening method of the present invention includes the following steps.
(1) The step of culturing the test substance in contact with the hair root part (2) The step of measuring the expression level of CXCL12 in the hair root part (3) The process of measuring the expression level of CXCL12 in the hair root part not contacting the test substance (4) A step of selecting a test substance whose expression level measured in the above step (2) is higher than the expression level measured in the above step (3) as a white hair prevention and / or improvement substance
まず工程（１）では、被験物質を毛髪の毛根部と接触させて培養する。接触は、被験物質を毛根部の細胞を含む培地に添加し、一定時間培養することにより行なう。スクリーニングに用いる被験物質は、主に化粧品及び／又は医薬品に利用できる成分を対象とし、例えば、動・植物組織の抽出物もしくは微生物培養物等の複数の化合物を含む混合物、またそれらから精製された標品；天然に生じる分子(例えば、アミノ酸、ペプチド、オリゴペプチド、ポリペプチド、タンパク質、核酸、脂質、ステロイド、糖タンパク質、プロテオグリカンなど）；あるいは天然に生じる分子の合成アナログ又は誘導体(例えば、ペプチド擬態物など)；及び天然に生じない分子(例えば、コンビナトリアルケミストリー技術等を用いて作製した低分子有機化合物)；ならびにそれらの混合物などを挙げることができる。また、被験物質としては単一の被験物質を独立に試験しても、いくつかの候補となる被験物質の混合物（ライブラリーなどを含む）について試験をしてもよい。複数の被験物質を含むライブラリーとしては、合成化合物ライブラリー、ペプチドライブラリーなどが挙げられる。 First, in step (1), the test substance is cultured in contact with the root of the hair. The contact is performed by adding the test substance to a medium containing cells at the hair root and culturing for a certain period of time. Test substances used for screening mainly target ingredients that can be used in cosmetics and / or pharmaceuticals, for example, mixtures containing a plurality of compounds such as extracts of animal and plant tissues or microbial cultures, and purified from them. Preparation; a naturally occurring molecule (eg, amino acid, peptide, oligopeptide, polypeptide, protein, nucleic acid, lipid, steroid, glycoprotein, proteoglycan, etc.); or a synthetic analog or derivative of a naturally occurring molecule (eg, peptidomimetic) And non-naturally occurring molecules (for example, low molecular weight organic compounds prepared using combinatorial chemistry techniques, etc.); and mixtures thereof. In addition, as a test substance, a single test substance may be tested independently, or a mixture of several candidate test substances (including a library) may be tested. Examples of the library containing a plurality of test substances include a synthetic compound library and a peptide library.
工程（２）及び（３）のＣＸＣＬ１２の発現量の測定、（４）の発現量に基づく評価は、前項の方法と同様に行えばよい。 The measurement of the expression level of CXCL12 in steps (2) and (3) and the evaluation based on the expression level in (4) may be performed in the same manner as in the method described in the previous section.
以下、実施例により本発明をさらに具体的に説明する。但し、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these.
（実施例１）毛包におけるCXCL12の発現部位の解析
ヒトの頭髪（黒髪）を毛抜きで採取し、PBS(-)にて2回洗浄した後、毛根部をメスで毛球、バルジ下、バルジ、バルジ上の4区画に分割した。Trizol Reagent(Invitrogen社製)によって各区画の細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、CXCL12の発現を確認した。その他の操作は定められた方法に従って実施した。
(Example 1) Analysis of CXCL12 expression site in hair follicle Human hair (black hair) was collected by tweezers, washed twice with PBS (-), and then the hair root was scalpeled with a scalpel, under bulge, bulge Divided into 4 sections on the bulge. RNA was extracted from cells in each compartment by Trizol Reagent (Invitrogen). Using 2-STEP real-time PCR kit (Applied Biosystems), the extracted RNA was reverse-transcribed to cDNA, and then ABI7300 (Applied Biosystems) was used to perform real-time PCR (95 ° C: 15 Second, 60 ° C .: 30 seconds, 40 cycles), and the expression of CXCL12 was confirmed. Other operations were carried out in accordance with established methods.
CXCL12用プライマーセット：
5'-CATGCCGATTCTTCGAAAGC-3' (配列番号３)
5'-CGAGTGGGTCTAGCGGAAAG-3' (配列番号４)
18srRNA(内部標準)用プライマーセット：
5'-CCGAGCCGCCTGGATAC-3' (配列番号５）
5'-CAGTTCCGAAAACCAACAAAATAGA-3'(配列番号６）
Primer set for CXCL12:
5'-CATGCCGATTCTTCGAAAGC-3 '(SEQ ID NO: 3)
5'-CGAGTGGGTCTAGCGGAAAG-3 '(SEQ ID NO: 4)
Primer set for 18srRNA (internal standard):
5'-CCGAGCCGCCTGGATAC-3 '(SEQ ID NO: 5)
5'-CAGTTCCGAAAACCAACAAAATAGA-3 '(SEQ ID NO: 6)
CXCL12の発現は、バルジにおけるCXCL12 mRNAの発現量を内部標準である18s ribosomal RNA（18srRNA）の発現量に対する割合として算出したCXCL12遺伝子相対発現量(CXCL12遺伝子発現量/18srRNA遺伝子発現量)の値を1とし、これに対し、その他の区画のCXCL12遺伝子相対発現量の値を算出し、評価した。これらの試験結果を以下の表１に示す。 The expression of CXCL12 is the relative expression level of CXCL12 gene (CXCL12 gene expression level / 18srRNA gene expression level) calculated as a ratio of the expression level of CXCL12 mRNA in the bulge to the expression level of 18s ribosomal RNA (18srRNA). On the other hand, the relative expression level of CXCL12 gene in the other compartments was calculated and evaluated. The test results are shown in Table 1 below.
表１に示すように、バルジ領域におけるCXCL12の発現は、他の区画と比較して顕著に高かった。 As shown in Table 1, CXCL12 expression in the bulge region was significantly higher compared to other compartments.
（実施例２）黒髪と白髪におけるCXCL12の発現量の比較
ヒトの黒髪と白髪をそれぞれ毛抜きで採取し、PBS(-)にて2回洗浄した後、Trizol Reagent(Invitrogen社製)によって毛根部の細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、前記のCXCL12用プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、CXCL12の発現を確認した。その他の操作は定められた方法に従って実施した。
(Example 2) Comparison of expression level of CXCL12 in black hair and white hair Human hair and white hair were collected by tweezers, washed twice with PBS (-), and then trizol Reagent (Invitrogen) made hair roots. RNA was extracted from the cells. Using 2-STEP real-time PCR kit (Applied Biosystems), the extracted RNA was reverse-transcribed to cDNA, and then ABI7300 (Applied Biosystems) was used to perform real-time PCR (95 ° C) using the above-mentioned primer set for CXCL12. : 15 seconds, 60 ° C .: 30 seconds, 40 cycles), and the expression of CXCL12 was confirmed. Other operations were carried out in accordance with established methods.
CXCL12の発現は、黒髪におけるCXCL12 mRNAの発現量を内部標準である18s ribosomal RNA（18srRNA）の発現量に対する割合として算出したCXCL12遺伝子相対発現量(CXCL12遺伝子発現量/18srRNA遺伝子発現量)の値を1とし、これに対し、白髪のCXCL12遺伝子相対発現量の値を算出し、評価した。これらの試験結果を以下の表２に示す。 The expression of CXCL12 is the relative expression level of CXCL12 gene (CXCL12 gene expression level / 18srRNA gene expression level) calculated as a ratio of the expression level of CXCL12 mRNA in black hair to the expression level of 18s ribosomal RNA (18srRNA). On the other hand, the relative expression level of CXCL12 gene in gray hair was calculated and evaluated. The test results are shown in Table 2 below.
表２に示すように、黒髪と比較して、白髪においてCXCL12の発現が顕著に低かった。 As shown in Table 2, the expression of CXCL12 was significantly lower in white hair than in black hair.
（実施例３）CXCL12による色素幹細胞分化抑制効果（１）
色素幹細胞モデルとしては、初期継代（継代数1〜4）のヒト正常メラノサイト(NHEM)を用いることができるため（Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE, Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell. 2010 Feb 5;6(2):130-40.）、継代数2のNHEMを用いた。Medium254(Thermo Fisher Scientific社製)に1%となるようにhuman melanocyte growth supplement(Thermo Fisher Scientific社製)を添加した培地(Medium254+)にて培養したNHEM(東洋紡社製)を、24ウェルプレートに4x104個ずつ播種し、24時間培養した。10 ng/mLとなるようにCXCL12を添加した新しいMedium254+に培地を交換し、さらに72時間培養した後、NHEMからRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、メラノサイト分化関連遺伝子（MITF、DCT、TYR）の発現を確認した。その他の操作は定められた方法に従って実施した。
(Example 3) CXCL12 suppresses pigment stem cell differentiation (1)
As a pigment stem cell model, human normal melanocytes (NHEM) in the early passage (passage number 1 to 4) can be used (Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J , Beermann F, Fisher DE, Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell. 2010 Feb 5; 6 (2): 130-40.), Passage 2 NHEM was used. NHEM (manufactured by Toyobo Co., Ltd.) cultured in a medium (Medium254 +) supplemented with human melanocyte growth supplement (manufactured by Thermo Fisher Scientific) to 1% to Medium 254 (manufactured by Thermo Fisher Scientific), 4 × 10 4 in a 24-well plate Four seeds were seeded and cultured for 24 hours. The medium was replaced with fresh Medium 254+ supplemented with CXCL12 at 10 ng / mL, and the cells were further cultured for 72 hours, and then RNA was extracted from NHEM. Using 2-STEP real-time PCR kit (Applied Biosystems), the extracted RNA was reverse-transcribed to cDNA, and then ABI7300 (Applied Biosystems) was used to perform real-time PCR (95 ° C: 15 Second, 60 ° C .: 30 seconds, 40 cycles), and the expression of melanocyte differentiation-related genes (MITF, DCT, TYR) was confirmed. Other operations were carried out in accordance with established methods.
MITF用プライマーセット：
5'-CGGGAAACTTGATTGATCT-3'(配列番号７)
5'-CTCTGTGGGAAAAATACACG-3' (配列番号８)
DCT用プライマーセット：
5'-GGAATGCTTTGGAAGGGTTTG-3' (配列番号９)
5'-AAAGCGTTTGTCCCGTTCAG-3' (配列番号１０)
TYR用プライマーセット：
5'-TGCGGTGGGAACAAGAAATC-3'(配列番号１１)
5'-GAAGAATGATGCTGGGCTGAGT-3'(配列番号１２)
Primer set for MITF:
5'-CGGGAAACTTGATTGATCT-3 '(SEQ ID NO: 7)
5'-CTCTGTGGGAAAAATACACG-3 '(SEQ ID NO: 8)
DCT primer set:
5'-GGAATGCTTTGGAAGGGTTTG-3 '(SEQ ID NO: 9)
5'-AAAGCGTTTGTCCCGTTCAG-3 '(SEQ ID NO: 10)
Primer set for TYR:
5'-TGCGGTGGGAACAAGAAATC-3 '(SEQ ID NO: 11)
5'-GAAGAATGATGCTGGGCTGAGT-3 '(SEQ ID NO: 12)
色素幹細胞分化抑制効果は、CXCL12を添加していないNHEMにおけるMITF mRNA、DCT mRNA、TYR mRNAの発現量を内部標準である18s ribosomal RNA（18srRNA）の発現量に対する割合として算出した遺伝子相対発現量(それぞれの遺伝子発現量/18srRNA遺伝子発現量)の値を1とし、これに対し、CXCL12を添加したNHEMにおける各遺伝子相対発現量の値を算出し、評価した。これらの試験結果を以下の表３に示す。 The pigment stem cell differentiation inhibitory effect is expressed in relative expression levels of genes calculated as the ratio of the expression levels of MITF mRNA, DCT mRNA, and TYR mRNA in NHEM without CXCL12 to the expression level of the internal standard 18s ribosomal RNA (18srRNA) ( The value of each gene expression level / 18srRNA gene expression level was set to 1, and the relative expression level of each gene in NHEM to which CXCL12 was added was calculated and evaluated. These test results are shown in Table 3 below.
表３に示すように、CXCL12を添加することにより、NHEMのメラノサイト分化関連遺伝子の発現が抑制された。このメラノサイト分化関連遺伝子の発現抑制は、CXCL12による色素幹細胞の分化抑制に起因すると考えられた。 As shown in Table 3, expression of NHEM melanocyte differentiation-related genes was suppressed by adding CXCL12. This suppression of melanocyte differentiation-related gene expression was thought to be due to the suppression of pigment stem cell differentiation by CXCL12.
（実施例４）CXCL12による色素幹細胞分化抑制効果（２）
ヒトの頭髪（黒髪）を毛抜きで採取し、外科用メスにてバルジ部位を採取し、0.25%トリプシン-EDTA中で30分間処理した。遠心操作によって得られた毛包幹細胞(hair follicle stem cell; HFSC)をHumedia-KG2（クラボウ社製）を用いて培養した。一定量まで増殖したHFSCを、0.25%トリプシン-EDTAを用いてシャーレから剥離し、遠心後、Humedia-KG2に懸濁して24ウェルプレートに5x104個ずつ播種した。24時間後、500 μLのOpti-MEM(Thermo Fisher Scientific社製)にCXCL12に対するsiRNA (siCXCL12：下記のsiRNA-1、siRNA-2、siRNA-3を混合して使用)又はネガティブコントロールのsiRNA(siNC, Bioneer社製)を50 nMとなるように添加し、さらにLipofectamine RNAiMAX(Thermo Fisher Scientific社製)を2 μL添加して懸濁し、20分後にHumedia-KG2と交換することでsiRNAをトランスフェクションした。
(Example 4) CXCL12 suppresses pigment stem cell differentiation (2)
Human hair (black hair) was collected by tweezers, the bulge site was collected with a scalpel and treated in 0.25% trypsin-EDTA for 30 minutes. Hair follicle stem cells (HFSC) obtained by centrifugation were cultured using Humedia-KG2 (Kurabo). HFSCs grown to a certain amount were detached from the petri dish using 0.25% trypsin-EDTA, centrifuged, suspended in Humedia-KG2, and seeded at 5 × 10 4 in 24-well plates. After 24 hours, siRNA against CXCL12 (siCXCL12: mix siRNA-1, siRNA-2, siRNA-3 below) or negative control siRNA (siNC) using 500 μL Opti-MEM (Thermo Fisher Scientific) , Bioneer) was added to 50 nM, and 2 μL of Lipofectamine RNAiMAX (Thermo Fisher Scientific) was added and suspended. After 20 minutes, siRNA was transfected by replacing with Humedia-KG2. .
<siRNA-1>
センス：GAUUCUUCGAAAGCCAUGU (配列番号１３）
アンチセンス：ACAUGGCUUUCGAAGAAUC (配列番号１４)
<siRNA-2>
センス：CCAGAGCCAACGUCAAGCA (配列番号１５）
アンチセンス：UGCUUGACGUUGGCUCUGG (配列番号１６）
<siRNA-3>
センス：CAACAGACAAGUGUGCAUU (配列番号１７）
アンチセンス：AAUGCACACUUGUCGGUUG (配列番号１８）
<siRNA-1>
Sense: GAUUCUUCGAAAGCCAUGU (SEQ ID NO: 13)
Antisense: ACAUGGCUUUCGAAGAAUC (SEQ ID NO: 14)
<siRNA-2>
Sense: CCAGAGCCAACGUCAAGCA (SEQ ID NO: 15)
Antisense: UGCUUGACGUUGGCUCUGG (SEQ ID NO: 16)
<siRNA-3>
Sense: CAACAGACAAGUGUGCAUU (SEQ ID NO: 17)
Antisense: AAUGCACACUUGUCGGUUG (SEQ ID NO: 18)
トランスフェクションから4時間後に、Opti-MEMを新しい500 μLのHumedia-KG2に置換し、48時間培養した。また、HFSCの培養と並行して、Medium254+を用いて培養したNHEMを、Medium254+に2x105個/mLとなるように懸濁し、24ウェルプレートの各ウェルに0.7mLのMedium254+を添加した上からセットしたポアサイズ0.4 μmのセルカルチャーインサートに4x104個ずつ播種した。48時間後、siRNAをトランスフェクションしたHFSCを培養している24ウェルプレートに、新しいMedium254+に交換したセルカルチャーインサートを移し、NHEMをHFSCと共培養した。また、コントロールとしては、HFSCを培養していない培地だけが入ったウェルに、NHEMを培養しているセルカルチャーインサートを移して培養した。72時間培養後、PBS(-)にて2回洗浄した後、Trizol Reagent(Invitrogen社製)によってNHEMからRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、前記のMITF、DCT、TYR 用各プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、CXCL12の発現を確認した。その他の操作は定められた方法に従って実施した。 Four hours after transfection, Opti-MEM was replaced with fresh 500 μL of Humedia-KG2, and cultured for 48 hours. In parallel with HFSC culture, NHEM cultured with Medium 254+ is suspended in Medium 254+ at 2x10 5 cells / mL, and 0.7 mL of Medium 254+ is added to each well of a 24-well plate. 4 × 10 4 cells were seeded on a cell culture insert having a pore size of 0.4 μm. After 48 hours, the cell culture insert replaced with fresh Medium 254+ was transferred to a 24-well plate in which HFSCs transfected with siRNA were cultured, and NHEM was co-cultured with HFSC. As a control, the cell culture insert in which NHEM was cultured was transferred to a well containing only a medium in which HFSC was not cultured. After culturing for 72 hours, after washing twice with PBS (−), RNA was extracted from NHEM with Trizol Reagent (manufactured by Invitrogen). Using the 2-STEP real-time PCR kit (Applied Biosystems), reverse-transcribe the extracted RNA to cDNA, and then use the above-mentioned primer sets for MITF, DCT, and TYR using ABI7300 (Applied Biosystems). Real-time PCR (95 ° C .: 15 seconds, 60 ° C .: 30 seconds, 40 cycles) was performed to confirm the expression of CXCL12. Other operations were carried out in accordance with established methods.
色素幹細胞分化抑制効果は、HFSCと共培養していないNHEMにおけるMITF mRNA、DCT mRNA、TYR mRNAの発現量を内部標準である18s ribosomal RNA（18srRNA）の発現量に対する割合として算出した遺伝子相対発現量(それぞれの遺伝子発現量/18srRNA遺伝子発現量)の値を1とし、これに対し、ネガティブコントロールのsiRNAをトランスフェクションしたHFSC（siNC-HFSC）と共培養したNHEM、CXCL12に対するsiRNAをトランスフェクションしたHFSC（siCXCL12-HFSC）と共培養したNHEMにおける各遺伝子相対発現量の値を算出し、評価した。これらの試験結果を以下の表４に示す。 The pigment stem cell differentiation inhibitory effect is expressed as the relative expression level of the gene expressed as the ratio of the expression level of MITF mRNA, DCT mRNA, and TYR mRNA in NHEM not co-cultured with HFSC to the expression level of the internal standard 18s ribosomal RNA (18srRNA). HFSC transfected with siRNA for NHEM and CXCL12 co-cultured with HFSC transfected with negative control siRNA (siNC-HFSC), with a value of (each gene expression level / 18srRNA gene expression level) The value of the relative expression level of each gene in NHEM co-cultured with (siCXCL12-HFSC) was calculated and evaluated. The test results are shown in Table 4 below.
表４に示すように、HFSCと共培養していないコントロールのNHEMと比較して、ネガティブコントロールのsiRNAをトランスフェクションしたHFSC（siNC-HFSC）と共培養したNHEMでは、メラノサイト分化関連遺伝子の発現が抑制された。一方、CXCL12に対するsiRNAをトランスフェクションしたHFSC（siCXCL12-HFSC）と共培養したNHEMでは、メラノサイト分化関連遺伝子の発現は抑制されず、コントロールと同程度であった。以上より、毛包幹細胞が産生するCXCL12が、メラノサイト分化関連遺伝子の発現抑制効果を示し、色素幹細胞の分化を抑制することが明らかとなった。 As shown in Table 4, compared to control NHEM not co-cultured with HFSC, NHEM co-cultured with negative control siRNA transfected HFSC (siNC-HFSC) showed melanocyte differentiation-related gene expression. Suppressed. On the other hand, in NHEM co-cultured with HFSC transfected with siRNA for CXCL12 (siCXCL12-HFSC), the expression of melanocyte differentiation-related genes was not suppressed and was similar to the control. From the above, it has been clarified that CXCL12 produced by hair follicle stem cells has an inhibitory effect on the expression of melanocyte differentiation-related genes and suppresses the differentiation of pigment stem cells.
本発明は、白髪の予防及び／又は改善を目的とした化粧品や医薬部外品の製造分野において利用できる。 INDUSTRIAL APPLICABILITY The present invention can be used in the field of manufacturing cosmetics and quasi-drugs for the purpose of preventing and / or improving gray hair.
Claims (8)
(ａ) 配列番号２に示すアミノ酸配列からなるタンパク質
(ｂ) 配列番号２に示すアミノ酸配列において、１若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質
(ｃ) 配列番号２に示すアミノ酸配列と８０％以上の配列同一性を有するアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質 The agent according to claim 1 or 2, wherein the CXCL12 is any one of the following proteins (a) to (c) or a partial peptide thereof.
(a) a protein comprising the amino acid sequence shown in SEQ ID NO: 2
(b) a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence shown in SEQ ID NO: 2 and having differentiation-inhibiting activity of pigment stem cells in the bulge region in the hair follicle
(c) a protein comprising an amino acid sequence having 80% or more of sequence identity with the amino acid sequence shown in SEQ ID NO: 2 and having an activity of inhibiting differentiation of pigment stem cells in the bulge region in hair follicle
（１）被験物質を毛髪の毛根部と接触させて培養する工程
（２）上記毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（３）被験物質を接触させない毛根部におけるＣＸＣＬ１２の発現量を測定する工程
（４）上記工程（２）で測定した発現量が、上記工程（３）で測定した発現量より増加した被験物質を白髪の予防及び／又は改善物質として選択する工程 A method for screening a substance for preventing and / or improving gray hair, comprising the following steps.
(1) The step of culturing the test substance in contact with the hair root part (2) The step of measuring the expression level of CXCL12 in the hair root part (3) The step of measuring the expression level of CXCL12 in the hair root part not contacting the test substance (4) A step of selecting a test substance whose expression level measured in the above step (2) is higher than the expression level measured in the above step (3) as a white hair prevention and / or improvement substance
The method according to any one of claims 4 to 6, wherein the expression level of the CXCL12 is measured by an immunological method using a protein extracted from the hair root as a sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016161060A JP6833193B2 (en) | 2016-08-19 | 2016-08-19 | Pigment stem cell differentiation inhibitor, gray hair preventive agent, and gray hair evaluation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016161060A JP6833193B2 (en) | 2016-08-19 | 2016-08-19 | Pigment stem cell differentiation inhibitor, gray hair preventive agent, and gray hair evaluation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018027920A true JP2018027920A (en) | 2018-02-22 |
| JP6833193B2 JP6833193B2 (en) | 2021-02-24 |
Family
ID=61248133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161060A Active JP6833193B2 (en) | 2016-08-19 | 2016-08-19 | Pigment stem cell differentiation inhibitor, gray hair preventive agent, and gray hair evaluation method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6833193B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019210245A (en) * | 2018-06-05 | 2019-12-12 | 日本メナード化粧品株式会社 | CXCL12 expression promoter |
| KR20200013273A (en) * | 2018-07-23 | 2020-02-07 | 아주대학교산학협력단 | Screening method for skin whitening agents using SDF1 promoter region |
-
2016
- 2016-08-19 JP JP2016161060A patent/JP6833193B2/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019210245A (en) * | 2018-06-05 | 2019-12-12 | 日本メナード化粧品株式会社 | CXCL12 expression promoter |
| JP7100351B2 (en) | 2018-06-05 | 2022-07-13 | 日本メナード化粧品株式会社 | CXCL12 expression promoter |
| KR20200013273A (en) * | 2018-07-23 | 2020-02-07 | 아주대학교산학협력단 | Screening method for skin whitening agents using SDF1 promoter region |
| KR102117504B1 (en) | 2018-07-23 | 2020-06-01 | 아주대학교산학협력단 | Screening method for skin whitening agents using SDF1 promoter region |
| US11692227B2 (en) | 2018-07-23 | 2023-07-04 | Ajou University Industry-Academic Cooperation Foundation | Method for screening for skin whitening agent by using SDF1 promoter region |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6833193B2 (en) | 2021-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5801406B2 (en) | Screening method for regulating adrenergic receptor gene expression involved in melanogenesis | |
| Botchkarev et al. | A role for p75 neurotrophin receptor in the control of apoptosis‐driven hair follicle regression | |
| JP6584494B2 (en) | Method for inhibiting HMGB1 activation of melanin producing cells, and method for identifying a drug suitable for such inhibition | |
| JP5027528B2 (en) | Test method for skin aging | |
| JP2014507132A (en) | Regulation of dynein in the skin | |
| JP2015028036A (en) | Substance for restoring normal co-expression and interaction between the lox and nrage proteins | |
| TW201323005A (en) | Modulation of thymosin beta-4 in skin | |
| KR20060123256A (en) | Method and composition for hair thickening | |
| JP6833193B2 (en) | Pigment stem cell differentiation inhibitor, gray hair preventive agent, and gray hair evaluation method | |
| JP2017536803A (en) | SESTRIN activator for prevention and / or alleviation of skin aging and / or moisturization of skin and / or suppression of skin pigmentation | |
| CN115227774A (en) | Use of Phalaenopsis amabilis extract for preparing composition for inhibiting formation of saccharification final product | |
| KR101883142B1 (en) | Composition for regulating cutaneous pigmentation or skin whitening comprising SDF1 | |
| US20110076303A1 (en) | Methods for Screening for Anti-Graying Agents on the Basis of AFF-4 | |
| EP2783212B1 (en) | Novel markers of papillary and reticular fibroblasts and uses thereof | |
| JP7015518B2 (en) | Hair follicle stem cell undifferentiated state maintainer | |
| KR20100126945A (en) | Composition of regenerating skin cell, method of manufacturing the same, method of regenerating skin cell and cosmetic composition | |
| US20160326492A1 (en) | Reconstituted nipple skin model | |
| Vishnyakova et al. | Hair growth stimulation by a natural remedy: Animal studies | |
| Hu et al. | Vitamins and their derivatives synergistically promote hair shaft elongation ex vivo via PlGF/VEGFR-1 signalling activation | |
| US20230167498A1 (en) | Method of determining the phenotype of a hair follicle | |
| JP2006223144A (en) | Method for screening hair-growing agent with prostaglandin f synthase and/or carbonyl reductase-1 as indicator | |
| WO2013147263A1 (en) | Novel use of acetyltransferase competitive inhibitory factor gm16515 | |
| TW201424766A (en) | PLOD-2 modulators and their use in the treatment of skin | |
| WO2014093053A1 (en) | Modulation of thymosin beta-4 in skin | |
| JP2002296267A (en) | Method of evaluating proposed substance for hair growth tinic, and method of manufacturing skin external remedy for hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200806 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210120 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6833193 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |